Novo Nordisk and Bluebird bio will collaborate to develop genome editing treatments for genetic diseases, citing specifically the bleeding disease hemophilia as a target disorder. The two companies did not disclose terms of their agreement. The three-year deal will focus initially on one-time treatments correcting mutations causing deficiencies in clotting Factor VIII, which causes hemophilia A. Novo Nordisk’s marketed product NovoEight treats this condition by replacing Factor VIII with an infusion as often as every other day. Novo’s portfolio of hemophilia treatments are under pressure as Roche’s Hemlibra, which can be dosed monthly, takes market share in hemophilia A. Learn More